首页 国际期刊 医学期刊 期刊详情(非官网)
400-808-1701

Lancet Oncology

Lancet Oncology杂志,由Lancet Publishing Group出版,于2000年创刊,Monthly,出版语言English,ISSN:1470-2045,E-ISSN:1474-5488。

投稿咨询
Lancet Oncology
Lancet Oncology
Lancet Oncology
SCI SCIE

杂志介绍

JCR分区
Q1
中科院分区
1区
影响因子
33.7
CiteScore
42
期刊收录
SCI、SCIE

Lancet Oncology(中文译名:《柳叶刀肿瘤学》),ISSN:1470-2045,EISSN:1474-5488,是Lancet Publishing Group出版的国际性学术期刊,创刊于2000年,以Monthly形式稳定发行,2026年总发文量约174篇。该刊采用非OA开放访问,学科归属为医学 - 肿瘤学。该刊是医学、肿瘤学领域的国际权威刊物,已被SCI(科学引文索引)、SCIE(科学引文索引扩展版)等国际主流学术数据库收录。2026年期刊影响因子达33.7,2025年期刊CiteScore为42,2025年期刊自引率约1.8%,在中科院期刊分区体系中位列医学大类1区TOP 期刊,在所属学科领域具备高学术影响力与国际认可度。Lancet Oncology长期聚焦医学、肿瘤学及相关产业的技术应用前沿,平均审稿周期一般,3-8周,审稿流程高效稳定。在稿件录用评判中,该刊将创新性与前沿性作为核心遴选标准,重点收录能够对医学、肿瘤学领域的落地与发展产生实质性推动价值的研究成果。

从全球发文格局来看,USAEngland、France、Italy、GERMANY (FED REP GER)、Canada、Australia等为核心发文国家与地区;HARVARD UNIVERSITYUNICANCER、UNIVERSITY OF LONDON、UNIVERSITY OF TEXAS SYSTEM、UNIVERSITY OF CALIFORNIA SYSTEM、MEMORIAL SLOAN KETTERING CANCER CENTER、UNIVERSITY OF TORONTO等高校与科研机构是期刊的主要发文单位。

期刊评价

名词解释:

影响因子(Impact Factor, IF):指该期刊前两年发表的文章,在第三年的平均被引用次数。它反映了期刊的近期平均影响力和热度。

中科院分区:中科院分区表是国内主流的学术期刊分级评价工具,核心意义是建立跨学科可比的统一评价标尺,为职称评审、学位授予、科研立项等科研管理工作提供标准化量化依据,同时帮助科研人员筛选优质期刊、规避学术风险,适配国内本土化的科研评价需求。

期刊分区表

《新锐期刊分区表》(2026年3月发布)

大类学科 小类学科 Top期刊 综述期刊
医学
1区
ONCOLOGY 肿瘤学
1区

期刊分区表(2025年3月升级版)

大类学科 小类学科 Top期刊 综述期刊
医学
1区
ONCOLOGY 肿瘤学
1区

期刊分区表(2023年12月升级版)

大类学科 小类学科 Top期刊 综述期刊
医学
1区
ONCOLOGY 肿瘤学
1区

JCR分区

2025-2026年最新版

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:ONCOLOGY SCIE Q1 9 / 333

97.4

学科:ONCOLOGY SCIE Q1 6 / 333

98.35

2024-2025年最新版

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:ONCOLOGY SCIE Q1 8 / 328

97.7

学科:ONCOLOGY SCIE Q1 4 / 328

98.93


中国学者近期发文

1
Fulzerasib plus cetuximab in first-line KRASG12C-mutated nonsmall-cell lung cancer (KROCUS): a single-arm, multicentre, phase 1b/2 tria

Author:Gregorc, Vanesa; Majem, Margarita; Lo Russo, Giuseppe; Maio, Michele; Salvagni, Stephanie; Gutiérrez-Calderon, Vanesa; Gonzalez-Cao, Maria; Contreras, Sergio Sandiego; Koumarianou, Anna; Bearz, Alessandra; Bernabé-Caro, Reyes; Viteri, Santiago; de Sanmamed, Miguel Fernández; Zagouri, Flora; Bueno, Teresa Morán; Lazzari, Chiara; Martínez-Recio, Sergio; Giménez-Capitán, Ana; Zhang, Yue; Shan, Yue; Zhu, Huaqiang; Zhao, Congqiao; Shen, Haige; Wang, Yu; Rosell, Rafael

Journal: LANCET ONCOLOGY. 2026; Vol. 27, Issue 4, pp. 432-441. DOI: 10.1016/S1470-2045(25)00764-8

2
Benmelstobart plus anlotinib versus pembrolizumab as first line treatment for PD-L1-positive, advanced non-small-cell lung cancer (CAMPASS): a blinded, randomised, controlled, phase 3tria

Author:Zhong, Hua; Wang, Jing; Yang, Runxiang; Luo, Yongzhong; Zuo, Wei; Zhang, Wei; Xie, Chao; Li, Qingshan; Liu, Qiang; Xu, Xingxiang; Wang, Qiming; Yu, Yan; Chen, Yongxing; Yi, Tienan; Min, Xuhong; Shi, Jinsheng; Yang, Jian; Sun, Hongmei; Chen, Hualin; Shi, Huaqiu; Gao, Junzhen; Shi, Jianhua; Zhang, Bo; Chu, Tianqing; Li, Kai; Han, Baohui

Journal: LANCET ONCOLOGY. 2026; Vol. 27, Issue 4, pp. 419-431. DOI: 10.1016/S1470-2045(26)00049-5

3
Fuzuloparib plus apatinib in BRCAmutated breast cancer: balancing efficacy and accessibility in regional Chin

Author:Qiu, Ziran; Jin, Na

Journal: LANCET ONCOLOGY. 2026; Vol. 27, Issue 3, pp. e125-e125. DOI: 10.1016/S1470-2045(25)00752-1

4
Fuzuloparib plus apatinib in BRCA- mutated breast cancer: balancing efficacy and accessibility in regional Chin

Author:Liu, Jieqiong; Liu, Yaxin; Song, Erwei; Li, Huiping

Journal: LANCET ONCOLOGY. 2026; Vol. 27, Issue 3, pp. e126-e126. DOI:

5
Vibostolimab coformulated with pembrolizumab versus pembrolizumab alone as adjuvant therapy for high-risk stage IIB-IV melanoma (KEYVIBE-010): a randomised double-blind, phase 3 stud

Author:Dummer, Reinhard; Guo, Jun; Luke, Jason J.; Carlino, Matteo S.; Schadendorf, Dirk; Khattak, Muhammad A.; Hauschild, Axel; Ascierto, Paolo A.; Chen, Yu; Shin, Sang Joon; Rutkowski, Piotr; Luo, Zhiguo; Chen, Jing; Rivalland, Gareth; Coetzee, Corlia; Ribas, Antoni; Mujika, Karmele; Markel, Gal; Villarroel, Rodrigo U.; Dizdar, Omer; Caglevic, Christian; Grebennik, Dmitri; Donovan, Kevin; Krepler, Clemens; Long, Georgina, V

Journal: LANCET ONCOLOGY. 2026; Vol. 27, Issue 3, pp. 327-339. DOI: 10.1016/S1470-2045(25)00709-0

6
Standardising MET amplification testing: limitations of the GCN ≥6 criterion Repl

Author:Wu, Yi-Long; Yao, Yu; Zhang, Pei-Long; Shi, He-Peng

Journal: LANCET ONCOLOGY. 2026; Vol. 27, Issue 3, pp. e128-e128. DOI:

7
Standardising MET amplification testing: limitations of the GCN ≥6 criterio

Author:Liu, Yuxin; Zhang, Dingdan; Tian, Shaodan

Journal: LANCET ONCOLOGY. 2026; Vol. 27, Issue 3, pp. e127-e127. DOI: 10.1016/S1470-2045(25)00758-2

8
International Multidisciplinary Consensus Group for Malignant Spinal Cord Compression: recommendations for definitions, reporting items, and study endpoints for clinical trials and audit

Author:Wong, Henry C. Y.; Choi, J. Isabelle; Marta, Gustavo Nader; Lee, Shing Fung; Chan, Adrian Wai; Santos, Monica D'alma Costa; Leung, Sheona; Wong, Edmond; Chan, Stephanie; Hircock, Caroline; Raman, Srinivas; Oldenburger, Eva; Simone Ii, Charles B.; Dearnaley, David; Maranzano, Ernesto; Chow, Edward; Rades, Dirk; Hoskin, Peter

Journal: LANCET ONCOLOGY. 2026; Vol. 27, Issue 2, pp. e111-e122. DOI: 10.1016/S1470-2045(25)00602-3

9
Aumolertinib as adjuvant therapy in resected EGFR-mutated non-small-cell lung cancer (ARTS): a double-blind, multicentre, randomised, controlled, phase 3 tria

Author:Zhang, Liang; Zhang, Xiqin; Wu, Lin; Xing, Wenqun; Liu, Chunling; Zhang, Peng; Chen, Kai; Shi, Jianhua; Xu, Shidong; Zhang, Xiaodong; Dong, Xiaorong; Fang, Haohui; Yu, Xinmin; Gao, Yang; Li, Gaofeng; Chen, Zhenming; Fan, Shaonan; Zhang, Xiaoqing; Cheng, Ying

Journal: LANCET ONCOLOGY. 2026; Vol. 27, Issue 2, pp. 159-168. DOI: 10.1016/S1470-2045(25)00643-6

10
Cilta-cel in lenalidomide-refractory multiple myeloma (CARTITUDE-4): an updated analysis including overall survival from an open-label, multicentre, randomised, phase 3 tria

Author:Einsele, Hermann; San-Miguel, Jesus; Dhakal, Binod; Touzeau, Cyrille; Leleu, Xavier; Donk, Niels Wcj Van De; Sidana, Surbhi; Oriol, Albert; Cohen, Yael C.; Harrison, Simon J.; Mateos, Maria-Victoria; Martinez-Lopez, Joaquin; Corradini, Paolo; Karlin, Lionel; Chen, Diana; Li, Quanlin; Yeh, Tzu-min; Li, Katherine; Plaks, Vicki; Slaughter, Ana; Lonardi, Carolina; Benachour, Nina; Ghosh, Arnab; Vogel, Martin; Schecter, Jordan M.; Lendvai, Nikoletta; Koneru, Mythili; Patel, Nitin; Florendo, Erika; Ho, Phoebe Joy; Popat, Rakesh

Journal: LANCET ONCOLOGY. 2026; Vol. 27, Issue 2, pp. 254-268. DOI: 10.1016/S1470-2045(25)00653-9


在线咨询

Lancet Oncology

国际简称:LANCET ONCOL参考译名:柳叶刀肿瘤学

年发文量:174 CiteScore:42 是否预警:否 Gold OA文章占比:16.03% 研究类文章占比:79.89%

杂志社联系方式:ELSEVIER SCIENCE INC, 360 PARK AVE SOUTH, NEW YORK, USA, NY, 10010-1710

Lancet Oncology